Evidence map›Paper›PMID 37738979›Full record

ArticleMed (New York, N.Y.)2023

A multi-country analysis of COVID-19 hospitalizations by vaccination status.

Bronner P Gonçalves, Waasila Jassat, Joaquín Baruch, Madiha Hashmi, Amanda Rojek, Abhishek Dasgupta, Ignacio Martin-Loeches, Luis Felipe Reyes, Chiara Piubelli, Barbara Wanjiru Citarella and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Med (New York, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Bronner P GonçalvesISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK. Electronic address: bronnergoncalves@gmail.com.
Waasila JassatNational Institute for Communicable Diseases, Johannesburg, South Africa; Right to Care, Pretoria, South Africa.
Joaquín BaruchISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Madiha HashmiCritical Care Asia and Ziauddin University, Karachi, Pakistan.
Amanda RojekISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Abhishek DasguptaDoctoral Training Centre, University of Oxford, Oxford, UK; Department of Biology, University of Oxford, Oxford, UK.
Ignacio Martin-LoechesDepartment of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St James's Hospital, Leinster, Dublin, Ireland; Pulmonary Intensive Care Unit, Respiratory Institute, Hospital Clinic of Barcelona, IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), University of Barcelona, CIBERes, Barcelona, Spain.
Luis Felipe ReyesUnisabana Center for Translational Science, School of Medicine, Universidad de La Sabana, Chía, Colombia.
Chiara PiubelliDepartment of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.
Barbara Wanjiru CitarellaISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Christiana KartsonakiMRC Population Health Research Unit, Clinical Trials Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Benjamin LefèvreUniversité de Lorraine, CHRU-Nancy, Service des Maladies Infectieuses et Tropicales, Nancy, France; Université de Lorraine, APEMAC, Nancy, France.
José W López RevillaInstituto Nacional del Niño San Borja and Facultad de Ciencias de la Salud, Universidad Científica del Sur, Lima, Peru.
Miles LunnISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Ewen M HarrisonCentre for Medical Informatics, The University of Edinburgh, Usher Institute of Population Health Sciences and Informatics, Edinburgh, UK.
Moritz U G KraemerDepartment of Biology, University of Oxford, Oxford, UK; Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Sally ShrapnelCentre for Health Services Research, Faculty of Medicine, The University of Queensland, Herston, Brisbane, Australia; School of Mathematics and Physics, Faculty of Science, The University of Queensland, St Lucia, Brisbane, Australia.
Peter HorbyISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Zeno BisoffiDepartment of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.
Piero L OlliaroISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Laura MersonISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
ISARIC Clinical Characterisation Group

Funding

Medical Research Council MC_PC_19059Medical Research Council MR/S032304/1Wellcome Trust
6 · The paper itself

Abstract

backgroundIndividuals vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), when infected, can still develop disease that requires hospitalization. It remains unclear whether these patients differ from hospitalized unvaccinated patients with regard to presentation, coexisting comorbidities, and outcomes.

methodsHere, we use data from an international consortium to study this question and assess whether differences between these groups are context specific. Data from 83,163 hospitalized COVID-19 patients (34,843 vaccinated, 48,320 unvaccinated) from 38 countries were analyzed.

findingsWhile typical symptoms were more often reported in unvaccinated patients, comorbidities, including some associated with worse prognosis in previous studies, were more common in vaccinated patients. Considerable between-country variation in both in-hospital fatality risk and vaccinated-versus-unvaccinated difference in this outcome was observed.

conclusionsThese findings will inform allocation of healthcare resources in future surges as well as design of longer-term international studies to characterize changes in clinical profile of hospitalized COVID-19 patients related to vaccination history.

fundingThis work was made possible by the UK Foreign, Commonwealth and Development Office and Wellcome (215091/Z/18/Z, 222410/Z/21/Z, 225288/Z/22/Z, and 220757/Z/20/Z); the Bill & Melinda Gates Foundation (OPP1209135); and the philanthropic support of the donors to the University of Oxford's COVID-19 Research Response Fund (0009109). Additional funders are listed in the "acknowledgments" section.

Indexed as

COVID-19HospitalizationHospitalsHumansSARS-CoV-2VaccinationcomorbidityCOVID-19descriptive epidemiologyheterogeneityTranslation to population healthvaccination

Identifiers

PMID37738979
PMCPMC10935543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.